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Connective tissue growth factor (CTGF) is involved in
mitogenesis, matrix production, and chemotaxis in
mesenchymal cells. The effects of CTGF on the production of
chemokines remain unclear. The present studies investigate
the regulatory role of CTGF in the production of fractalkine,
monocyte chemoattractant protein-1 (MCP-1), and RANTES
(regulated upon activation, normal T cell expressed and
secreted) in cultured mesangial cells of rats, and the
modulatory effects of lipoxin A4 (LXA4) on actions of CTGF.
CTGF enhanced the mRNA expression and protein release of
fractalkine, MCP-1, and RANTES, the expression of phospho
(P)-p42/44 mitogen-activated protein kinase (MAPK),
P-phosphoinositide 3-kinase (PI3-K), P-Akt, and activity of
nuclear factor-jB (NF-jB) in mesangial cells. P-p42/44 MAPK
blockade inhibited the CTGF-induced expression of P-p42/44
MAPK but not NF-jB, and partially decreased the levels of the
above chemokines in supernatants. P-PI3-K blockade
downregulated the CTGF-stimulated expression of P-PI3-K,
P-Akt, and NF-jB but not P-p42/44 MAPK, and partially
decreased the release of the above chemokines. NF-jB
blockade abrogated the CTGF-activated NF-jB and partially
decreased the secretion of the above chemokines. LXA4
dose-dependently inhibited the CTGF-stimulated mRNA
expression and protein release of the above chemokines, and
the expression of P-p42/44MAPK, P-PI3-K, P-Akt, and NF-jB.
In conclusion, these results demonstrate that CTGF induces
production of fractalkine, MCP-1, and RANTES via the p42/44
MAPK-, PI3-K/Akt-, and NF-jB-dependent signal pathway,
and LXA4 downregulates the above effects of CTGF on rat
mesangial cells.
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Connective tissue growth factor (CTGF) is a profibrotic
cytokine implicated in multiple cellular events including
mitogenesis and chemotaxis in mesenchymal cells, and may
be particularly relevant to renal fibrosis.1 Transforming
growth factor-b increased monocyte chemoattractant pro-
tein-1 (MCP-1), and RANTES (regulated upon activation,
normal T cell expressed and secreted) expression in renal
tubular cells.2 Accumulating data suggested that fractalkine,
MCP-1, and RANTES played an important role in the
pathogenesis of renal fibrosis.3–8 However, relatively little is
known about the effects of CTGF, a crucial mediator for
transforming growth factor-b,1 on the production of
fractalkine, MCP-1 and RANTES. It remains unclear whether
CTGF indirectly promotes renal fibrosis via production of
fractalkine, MCP-1 and RANTES besides the direct pro-
fibrotic role of CTGF. Lipoxin A4 (LXA4) has pleiotropic
bioactions including antifibrotic actions,9 and has been
shown to inhibit mesangial cell proliferation induced by
platelet-derived growth factor, tumor necrosis factor-a (TNF-a),
and leukotriene D4.
10–12 It was demonstrated that LXA4
attenuated TNF-a-stimulated release of MCP-1 and RANTES
in human intestinal mucosa.13 It remains unclear whether
LXA4 inhibits the secretion of fractalkine, MCP-1, and
RANTES in mesangial cells and modulates the action of
CTGF. The current studies were therefore undertaken to find
out whether CTGF could stimulate the synthesis of fractalk-
ine, MCP-1, and RANTES by rat mesangial cells and whether
LXA4 could modulate the production of the above chemo-
kines by mesangial cells, and to examine the involvement of
the p42/44 mitogen-activated protein kinase (MAPK),
phosphoinositide 3-kinase (PI3-K)/Akt, and nuclear factor-
kB (NF-kB) pathway in CTGF and LXA4 actions. Murine
LXA4 receptor homologue gene (LRHG) was recently
identified, cloned, and functionally characterized by Vaughn
et al.,14 and their data indicated that cDNA of LRHG shared
89% sequence identity with murine LXA4 receptor and
encoded LXA4 homologue receptor, which functionally
responded to LXA4 as a ligand. The present studies
were performed to explore whether transfection of LRHG
into mesangial cells could change the effects of LXA4 on the
cells.
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RESULTS
Expression of fractalkine, MCP-1, and RANTES mRNA
in response to CTGF and LXA4
As shown in Figure 1a–c, CTGF increased the mRNA
expression of fractalkine, MCP-1, and RANTES in a time-
dependent manner in cultured mesangial cells. In Figure 1d,
the expression of fractalkine, MCP-1, and RANTES peaked at
12, 6, and 6 h, respectively. As shown in Figure 2a–c, LXA4
downregulated the mRNA expressions of fractalkine, MCP-1,
and RANTES in the mesangial cells stimulated by CTGF in a
dose-dependent manner. Data of semiquantitative analysis
using UVP-gel densitometry are shown in Figure 2d. The
inhibitory effect of LXA4 at 100 nmol/l was similar to that of
LXA4 at 10 nmol/l (data not shown).
Release of soluble fractalkine, MCP-1, and RANTES
in response to CTGF and LXA4
As shown in Figure 1e, CTGF increased the secretion of
soluble fractalkine, MCP-1, and RANTES proteins in the
supernatants of mesangial cells in a time-dependent manner,
and all the chemokines peaked at 24 h. CTGF dose-
dependently upregulated the release of the above chemokines,
as shown in Figure 1f. Pretreatment of the cells with PD98059
or LY294002 for 30 min, or PDTC for 1 h, partially but
significantly decreased the CTGF-induced increments of the
above chemokines in supernatants. As indicated in Figure 2e,
LXA4 inhibited the release of soluble fractalkine, MCP-1, and
RANTES from the mesangial cells stimulated by CTGF in a
dose-dependent manner. The inhibitory effect of LXA4 at
100 nmol/l was similar to that of LXA4 at 10 nmol/l (data not
shown). Furthermore, transfection of LRHG into the cells
intensified the inhibitory effects of LXA4 on CTGF-induced
release of the above chemokines, as shown in Figure 3.
Regulation of phospho (P)-p42/44 MAPK, P-PI3-K, and P-Akt
by CTGF and LXA4
As shown in Figure 4a–c, mesangial cells stimulated with
CTGF displayed rapid and transient phosphorylation of p42/
44 MAPK, PI3-K, and Akt, reaching maximal levels by 10, 5,
and 10 min, respectively, as shown in Figure 4d, similar to the
results reported by Crean et al.15 and Wahab et al.16 CTGF
upregulated the expression of P-p42/44 MAPK, P-PI3-K, and
P-Akt in a dose-dependent manner, as shown in Figure 4e–g.
When cells were pretreated with PD98059, a specific P-p42/44
MAPK inhibitor,17 CTGF-induced phosphorylation of p42/
44 MAPK was inhibited but not that of PI3-K or Akt. When
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Figure 1 | (a–d) CTGF stimulates mRNA expression of fractalkine, MCP-1, and RANTES in a time-dependent manner and (e) release of
soluble fractalkine, MCP-1, and RANTES in a time-dependent, and (f) a dose-dependent manner. Cultured and quiescent mesangial cells
were exposed to CTGF for (a–d) 2–24 h, (e) 6–48 h, or 24 h, with or without preincubation with PD98059, LY294002, and pyrrolidine
dithiocarbamate (PDTC). (f) Expression of mRNA was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). In (a–c), the upper
panels show RT-PCR products from glyceraldehyde-3-phosphate dehydrogenase (GAPDH), served as an internal control for RNA expression.
Results shown are representative of four independent experiments. (d) Data of semiquantitative analysis using UVP-gel densitometry are
shown. (e, f) Release of chemokines in the conditioned media was assessed by enzyme-linked immunosorbent assay (ELISA) are shown. Values
are mean7s.e.m. of four experiments. *Po0.05, compared to the cells (measured for same kind of chemokine) treated with 0.5% fetal calf
serum (FCS) alone. #Po0.05, compared to the cells (measured for same kind of chemokine) treated with 0.5% FCS and CTGF (50 ng/ml) without
PD98059, LY294002, or PDTC.
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cells were preincubated with LY294002, a selective PI3-K
inhibitor,15 CTGF-stimulated phosphorylation of PI3-K and
Akt was blocked but not that of p42/44 MAPK. As indicated
in Figure 5, LXA4 downregulated the phosphorylation of p42/
44 MAPK, PI3-K, and Akt induced by CTGF in mesangial
cells in a dose-dependent manner. Furthermore, transfection
of LRHG into the cells intensified the inhibitory effects of
LXA4 on CTGF-induced phosphorylation of p42/44 MAPK,
PI3-K, and Akt, as shown in Figure 6.
Regulation of DNA-binding activity of NF-jB by CTGF
and LXA4
CTGF upregulated the DNA-binding activity of NF-kB with
nuclear extracts from mesangial cells, as shown in Figure 7.
The specificity of the binding reaction was confirmed in
competition experiments by the ability of excess unlabeled
NF-kB oligonucleotide probe to inhibit the binding. PDTC,
an NF-kB inhibitor,17 completely and LY294002 partially
inhibited the CTGF-induced increment of activity of NF-kB,
whereas PD98059 did not. LXA4 downregulated the DNA-
binding activity of NF-kB induced by CTGF in a dose-
dependent manner.
Chemotactic effects of the conditioned media on monocyte
transmigration
In vitro chemotaxis assay showed monocyte migration in
response to the conditioned media of cells treated with CTGF,
as shown in Figure 8. When the conditioned media were
preincubated with an anti-fractalkine, anti-MCP-1, or anti-
RANTES neutralizing antibodies for 30 min, monocyte
migration was partially attenuated. The effects of anti-
fractalkine, anti-MCP-1, and anti-RANTES were additive so
that the conditioned media preincubated with the three
antibodies together amplified the neutralizing role on
monocyte migration induced by CTGF. In contrast, pre-
incubating the conditioned media with the goat IgG did not
affect monocyte transmigration. As shown in Figure 9,
pretreatment of the cells with LXA4 dose-dependently
decreased the CTGF-induced chemotactic effects of the
conditioned media on monocyte transmigration. Transfec-
tion of LRHG into the cells significantly intensified the
inhibitory effect of LXA4 (10 nmol/l) on CTGF-induced
monocyte transmigration.
DISCUSSION
CTGF, a potential profibrotic cytokine, is a crucial media-
tor for transforming growth factor-b-induced cellular
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Figure 2 | (a–c) LXA4 downregulates mRNA expression of
fractalkine, MCP-1, RANTES and (e) release of soluble fractalkine,
MCP-1, and RANTES. Quiescent mesangial cells were exposed to
CTGF for (a) 12 h, (b, c) 6 h, or (e) 24 h, with or without preincubation
with LXA4 for 30 min. Expressions of mRNA were analyzed by RT-PCR.
In (a–c), the upper panels show RT-PCR products from GAPDH, served
as an internal control for RNA expression. Results shown are
representative of four independent experiments. (d) Data of
semiquantitative analysis using UVP-gel densitometry are shown.
(e) Release of chemokines in the conditioned media was assessed by
ELISA. Values are mean7s.e.m. of four experiments. *Po0.05,
compared to the cells (measured for same kind of chemokine) treated
with 0.5% FCS alone. #Po0.05, compared to the cells (measured
for same kind of chemokine) treated with 0.5% FCS and CTGF
without LXA4.
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Figure 3 | Transfection of LRHG into the cells intensified the
inhibitory effects of LXA4 on CTGF-induced release of fractalkine,
MCP-1, and RANTES. Growth-arrested mesangial cells were exposed
to CTGF for 24 h, with or without preincubation with LXA4 for 30 min.
Release of chemokines in the conditioned media was assessed by
ELISA. Values are mean7s.e.m. of four experiments. *Po0.05,
compared to the cells (measured for same kind of chemokine)
transfected with empty vector and treated with CTGF. #Po0.05,
compared to the cells (measured for same kind of chemokine)
transfected with empty vector and treated with CTGF and LXA4.
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dysfunction.1 Although it was reported that transforming
growth factor-b increased MCP-1 and RANTES mRNA and
peptide levels in renal tubular cells,2 it remains unclear
whether CTGF induces production of MCP-1, RANTES, and
fractalkine. In the present studies, we demonstrated that
CTGF stimulated the production of fractalkine, MCP-1, and
RANTES in rat mesangial cells in vitro. First, CTGF
upregulated the mRNA expression of the above chemokines
(Figure 1a–d). Furthermore, CTGF increased the concentra-
tions of the above chemokines in the supernatants of cultured
cells in a time- and a dose-dependent manner (Figure 1e
and f). Finally, the above chemokines in the conditioned
media functionally promoted monocyte transmigration, as
pretreatment of the conditioned media with anti-fractalkine,
anti-MCP-1, or anti-RANTES antibodies abrogated monocyte
transmigration (Figure 8). Previous investigations indicated
that fractalkine, MCP-1, and RANTES promote renal fibrosis
via the increment in infiltration and activation of monocytes/
macrophages.3–8 The present studies provided a speculation
that CTGF may indirectly promote renal fibrosis via
production of fractalkine, MCP-1, and RANTES besides the
direct profibrotic role of CTGF. Further studies are needed to
examine whether this may have in vivo relevance.
Several inhibitors of CTGF expression have been reported,
including TNF-a, nitric oxide, prostaglandin E2, and
iloprost.1,18 LXA4 acts as an endogenous potential anti-
inflammatory and antifibrotic mediator.9 For example, LXA4
attenuated TNF-a-stimulated release of MCP-1 and RANTES
in human intestinal mucosa.13 In the current studies, we
reported that LXA4 inhibited CTGF-induced production of
fractalkine, MCP-1, and RANTES in rat mesangial cells. First,
LXA4 downregulated the CTGF-stimulated mRNA expression
of the above chemokines in a dose-dependent manner
(Figure 2a–d). Furthermore, LXA4 inhibited the CTGF-
evoked release of the above chemokines in the supernatants
of the cells (Figure 2e). Finally, LXA4 dose-dependently
decreased monocyte transmigration in response to the
conditioned media of the cells stimulated by CTGF (Figure 9).
Murine LRHG reported by Vaughn et al.14 shared 89%
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Figure 4 | (a–c) CTGF upregulates the expression of P-p42/44
MAPK, P-PI3-K, and P-Akt in a time-dependent manner and (e–g)
a dose-dependent manner. Serum-restricted mesangial cells were
exposed to CTGF for (a–c) 5–30 min, (e, g) 10 min, or (f) 5 min, with or
without preincubation with PD98059 or LY294002. Total and
phosphorylated p42/44 MAPK, PI3-K, and Akt were analyzed by
Western blotting. Results shown are representative of four
independent experiments. (d) Data of semiquantitative analysis using
UVP-gel densitometry are shown. Values are mean7s.e.m. of four
experiments.
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Figure 5 | LXA4 downregulates CTGF-induced expressions of
P-p42/44 MAPK, P-PI3-K, and P-Akt. Growth-arrested mesangial
cells were exposed to CTGF for (a, c) 10 min or (b) 5 min, with or
without preincubation with LXA4 for 30 min. Total and phosphory-
lated p42/44 MAPK, PI3-K, and Akt were analyzed by Western
blotting. Results shown are representative of four independent
experiments. (d) Data of semiquantitative analysis using UVP-gel
densitometry are shown. Values are mean7s.e.m. of four experi-
ments. *Po0.05, compared to the cells (measured for same kind of
chemokine) treated with 0.5% FCS alone. #Po0.05, compared to the
cells (measured for same kind of chemokine) treated with 0.5% FCS
and CTGF without LXA4.
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sequence identity with murine LXA4 receptor and encoded
LXA4 homologue receptor, which functionally responded to
LXA4 as a ligand. Data in the present studies suggested that
LXA4 homologue receptor was involved in the inhibitory role
of LXA4 in CTGF-induced production of chemokines, as
transfection of pcDNA3.1/LRHG vector into the cells
intensified the inhibitory effects of LXA4 on CTGF-induced
release of chemokines (Figure 3) and CTGF-induced
chemotactic ability of the conditioned media on monocyte
migration (Figure 9). Previous studies showed that LXA4
increased monocyte migration and adherence to laminin.19,20
However, we failed to find that the conditioned media from
the cells treated with LXA4 alone increased monocyte
migration (Figure 9). This discrepancy may be due to the
different methods adopted in the previous studies19,20 and
the present studies. In the previous studies, LXA4 was directly
added to lower chemotaxis chamber and immediately
incubated with monocytes in upper chemotaxis chamber
for 90 min.19,20 In the present studies, lower chemotaxis
chamber was filled with conditioned media, which came
from the supernatants of the cells treated with LXA4 for 24 h
plus 30 min (Figure 9). As LXA4 is rapidly inactivated by
cells,21 we failed to find that conditioned media derived from
the cells treated with LXA4 for a long time increased
monocyte migration. Recently, it was demonstrated that
LXA4 inhibited TNF-a-induced release of MCP-1 and
RANTES by human intestinal mucosa, which may result in
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Figure 8 | Conditioned media from the cells treated with CTGF
promote monocyte transmigration. Conditioned media were
obtained by incubating the cells with CTGF for 24 h. Abilities of
monocyte migration were assessed by in vitro chemotaxis assay.
Similar studies were performed after the conditioned media were
pretreated with the goat anti-fractalkine, anti-MCP-1, anti-RANTES, or
goat IgG for 30 min. Data are mean7s.e.m. based on five separate
experiments carried out in duplicate. *Po0.05, compared to the
cells treated with 0.5% FCS alone. #Po0.05, compared to the cells
treated with 0.5% FCS and CTGF (50 ng/ml) without antibodies.
HPF: high-power field.
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a decreased infiltration of monocytes.13 As infiltration and
activation of monocytes/macrophages induced by fractalkine,
MCP-1, and RANTES are the major mechanisms for injury in
the experimental glomerulonephritis models and human
renal diseases,3–8 the inhibitory role of LXA4 in the
production of fractalkine, MCP-1, and RANTES may be
beneficial to the treatment of glomerulonephritis.
Recent experiments revealed that CTGF activated several
signaling pathways such as p42/44 MAPK, PI3-K, protein
kinase (PK) B (Akt), PKC, and Jun NH2-terminal kinase but
not p38 MAPK, and TrkA serves as a tyrosine kinase receptor
for CTGF.1,16 The present studies indicated that CTGF-
induced production of chemokines was mediated by activa-
tion of p42/44 MAPK (Figure 4a and e) because PD98059
decreased CTGF-induced p42/44 MAPK phosphorylation
(Figure 4e) as well as the release of soluble fractalkine, MCP-1,
and RANTES in supernatants (Figure 1f) at a concentra-
tion that did not attenuate phospho-PKC or nuclear
translocation of p65/NF-kB.17 However, PD98059 did not
inhibit the activation of NF-kB induced by CTGF (Figure 7).
Usually, NF-kB could be activated by p38 MAPK,22 whereas
p38 MAPK was not affected by CTGF.1 Although inhibition
of the p42/44 MAPK pathway abolished both NF-kB
activation and chemokine upregulation in macrophages
stimulated by hemozoin,23 PD98059 failed to affect TNF-a-
induced degradation of IkBa or NF-kB nuclear translocation
in the production of fractalkine by mesangial cells.17
Consistently, data in the present studies showed that
PD98059 did not inhibit NF-kB activation induced by CTGF,
suggesting that the p42/44 MAPK pathway was in parallel to
the NF-kB pathway in the production of chemokines by
mesangial cells stimulated by CTGF. In the current studies,
activation of NF-kB was indispensable to CTGF-induced
chemokine expression, as pretreatment of the cells with
PDTC abolished the CTGF-induced activation of NF-kB
(Figure 7) and the increment of chemokines in supernatants
(Figure 1f). It has been shown that Akt was a downstream
target of PI3-K, and NF-kB was the principal contributor to
the downstream activation of the PI3-K/Akt pathway, as PI3-
K/Akt promotes IkB kinase and NF-kB transcription.24
Indeed, pretreatment of the cells with LY294002 blocked
CTGF-stimulated activation of PI3-K, Akt (Figure 4f and g)
and NF-kB (Figure 7), and partially decreased the release of
the above chemokines (Figure 1f), indicating that PI3-K/Akt
and NF-kB mediated CTGF-induced production of chemo-
kines in mesangial cells. The involvement of PI3-K/Akt in
p42/44 MAPK activation has not consistently been found.
The PI3-K/Akt pathway blockade prevented activation of
p42/44 MAPK in platelet-derived growth factor-induced
mesangial cell migration25 and in placenta growth factor-
induced monocyte activation.26 In contrast, PI3-K blockade
by LY294002 failed to inhibit p42/44 MAPK activation of
human mesangial cells in response to CTGF.15 Consistent
with the latter investigation, data in the present studies
showed that LY294002 did not inhibit p42/44 MAPK
activation induced by CTGF, as shown in Figure 4e.
NF-kB-binding site on the promoter of fractalkine, MCP-1,
and RANTES was documented by previous investiga-
tions.27–29 Studies have indicated that productions of
fractalkine, MCP-1, and RANTES were NF-kB- and/or
MAPK-dependent. In rat mesangial cells, expression of
fractalkine mRNA and protein stimulated by TNF-a was
mediated by activation of p42/44 MAPK and NF-kB.17 In
proximal tubular cells, protein overload-induced upregula-
tion of fractalkine was p38 MAPK- and NF-kB-dependent,
and albumin- and IgG-induced upregulation of MCP-1 and
RANTES was through the NF-kB-dependent pathway.30 Uric
acid stimulated MCP-1 production in vascular smooth
muscle cells via the p42/44 MAPK, p38 MAPK, and NF-kB
signal pathway.31 Placenta growth factor-induced upregula-
tion of MCP-1 was through the p42/44 MAPK and PI3-K/Akt
but not the p38 MAPK pathway.26 In rat model of renal
inflammation, expression, and secretion of RANTES in
glomeruli were correlated with an increased activity of NF-
kB.29 As p38 MAPK was not activated by CTGF,1 we did not
assess the expression of p38 MAPK in the present studies.
Our results were consistent with the above observations. The
mRNA and protein expressions of fractalkine, MCP-1, and
RANTES in rat mesangial cells treated with CTGF were p42/
44 MAPK and NF-kB pathway-dependent (Figures 1e, 4e,
and 7).
LXA4 modulated the expression of cytokines, growth
factors, and chemokines via many signal pathways.9 In the
present studies, LXA4 dose-dependently downregulated the
activation of p42/44 MAPK, PI3-K/Akt, and NF-kB induced
by CTGF (Figures 5 and 7), concomitant with the inhibitory
role of LXA4 in mRNA expression and protein release
of fractalkine, MCP-1, and RANTES stimulated by
CTGF (Figure 2). Our data were supported by previous
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Figure 9 | Transfection of LRHG into the cells intensified the
inhibitory effects of LXA4 on monocyte transmigration in
response to the conditioned media from the cells treated with
CTGF. Conditioned media were obtained by incubating the cells with
CTGF for 24 h with or without preincubation with LXA4 for 30 min.
The cells were transfected with recombinant plasmid pcDNA3.1/
LRHG-his or empty pcDNA3.1 vector before being treated with CTGF
and/or LXA4. Abilities of monocyte migration were assessed by in
vitro chemotaxis assay. Data are mean7s.e.m. based on five separate
experiments carried out in duplicate. *Po0.05, compared to the
cells treated with 0.5% FCS alone. #Po0.05, compared to the cells
treated with 0.5% FCS and CTGF (50 ng/ml) without LXA4. DPo0.05,
compared to the cells transfected with empty pcDNA3.1
vector and treated with 0.5% FCS, CTGF, and LXA4 (10 nmol/l).
HPF: high-power field.
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investigation, which showed that LXA4 inhibited TNF-a-
evoked NF-kB activation in rat mesangial cells,12 and
activation of LXA4 receptor inhibited TNF-a-induced activa-
tion of NF-kB in embryonic kidney 293 cells.32 It was also
demonstrated that LXA4 inhibited platelet-derived growth
factor-induced PI3-K and Akt/PKB activation,10 and inhibited
leukotriene D4-induced PI3-K and Ras activation.
11 Ras is an
upstream GTPase of MAPK kinase/extracellular signal-regu-
lated kinase 1/2 (p42/44 MAPK).33 This mechanism may
contribute to the inhibition of LXA4 on activation of p42/44
MAPK in the present studies. In the current studies, LXA4 itself
slightly upregulated the phosphorylation of p42/44 MAPK
(Figure 5a) – as previously reported by McMahon et al.11 – but
to an extent less than the effect of CTGF (Figure 5d). As shown
in Figure 6, transfection of pcDNA3.1/LRHG vector into the
cells intensified the inhibitory effects of LXA4 on CTGF-
induced phosphorylation of p42/44 MAPK, PI3-K, and Akt,
suggesting that LXA4 homologue receptor was involved in the
action of LXA4. The functional interaction between CTGF and
LXA4 involves LXA4 modifying the signaling pathway of CTGF
rather than the binding of CTGF on the cells, as receptors of
CTGF1,16 are different from those of LXA4.
11
In conclusion, our studies demonstrated that CTGF-
induced production of fractalkine, MCP-1, and RANTES in
rat mesangial cells can be inhibited by LXA4 via p42/44
MAPK, PI3-K/Akt, and NF-kB pathway-dependent signal
transduction. As fractalkine, MCP-1, and RANTES played an
important role in the pathogenesis of renal fibrosis,3–8 our
data further expand on the antifibrotic repertoire of lipoxins,
which are useful tools for the development of a new therapy
in the treatment of glomerulonephritis.9
MATERIALS AND METHODS
Materials and reagents
Rat mesangial cell lines were purchased from Wuhan University,
Wuhan, China. Acute monocytic leukemia cell lines (THP-1) were
obtained from Shanghai Institute of Cell Biology, Chinese Academy of
Sciences. Trizol, Moloney-murine leukemia virus reverse transcription
enzyme, dNTP, Oligo(dT)15, RNasin, rat MCP-1 ELISA kit, pGEM-
T-easy vector, [g-32P]ATP, T4 polynucleotide kinase, and Gel Shift
Assay kit were purchased from Promega (Madison, WI, USA).
Advantage 2 DNA polymerase and pcDNA3.1/myc-his vector were
obtained from BD Biosciences (La Jolla, CA, USA). Restriction
endonucleases HindIII and XhoI were purchased from New England
BioLab (Beverly, MA, USA). Endo-free Plasmid Maxi kit was
obtained from Qiagen (Hilden, Germany). DNA Ligation kit ver
2.1 was purchased from Takara (Osaka, Japan). Lipofectamine 2000
reagent was obtained from Invitrogen (Carlsbad, CA, USA). Nuclear
Protein Extraction kit was purchased from Active Motif (Carlsbad,
CA, USA). Rabbit anti-rat threonine/tyrosine diphosphorylated p42/
44 MAPK, total p42/44 MAPK, serine phosphorylated Akt, total Akt,
tyrosine phosphorylated PI3-K p85, total PI3-K p85, and
6 histidine antibodies, goat anti-rabbit IgG, and double-stranded
oligonucleotide probes of NF-kB were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Enhanced chemiluminescence
reagent system and polyvinylidene difluoride membranes were
obtained from Amersham (Arlington, IL, USA). CTGF was purchased
from Fibrogen (San Francisco, CA, USA). Rat fractalkine ELISA kit, goat
anti-rat fractalkine, MCP-1, and RANTES antibodies, and goat IgG were
obtained from R&D systems (Minneapolis, MN, USA). Rat RANTES
ELISA kit was purchased from Biosource (Camarillo, CA, USA).
PD98059, LY294002, and PDTC were obtained from Calbiochem (La
Jolla, CA, USA). LXA4 was purchased from Sigma (St Louis, MO, USA).
Culture of rat mesangial cells
Mesangial cell monolayers were cultured in RPMI-1640 medium
containing 10% FCS at 371C in a 5% CO2 incubator. These cells held
the phenotypic characteristics of mesangial cells, including stellate
morphology, desmin, vimentin, and Thy1.1 antigen expression, as
described previously.12 Cells were growth-arrested by incubation in
RPMI-1640 containing 0.5% FCS for 48 h before they were
stimulated by CTGF. Cell viability was measured by Trypan blue
exclusion assay in a pilot experiment and the percentage of viable
cells was more than 90% after exposure to LXA4 (10 nmol/l) or
CTGF (50 ng/ml) for 24 h, PD98059 (40 mmol/l) or LY294002
(25mmol/l) for 30 min, and PDTC (50 mmol/l) for 1 h.
Reverse transcription-polymerase chain reaction of chemo-
kines
Cells (2 106/well) were harvested and RNA was extracted and
reverse transcribed as described previously.12 RT-PCR was per-
formed with the following sets of primers for rat fractalkine, 50-
GGCCTTTCTTGGTCTACTCT-30 (sense) and 50-CCACCTGCTCT
GTCTGTCT-30 (antisense) amplifying a 363-bp fragment, for rat
MCP-1, 50-CTCAGCCAGATGCAGTTA-30 (sense) and 50-TGGA
AGGGAATAGTGTAAT-30 (antisense) amplifying a 453-bp frag-
ment, for rat RANTES, 50-CTCACCGTCATCCTCGTT-30 (sense)
and 50-CTAGCTCATCTCCAAATAGTT-30 (antisense) amplifying a
255-bp fragment. The rat GAPDH was used as an internal control,
50-ACCACAGTCCATGCCATCAC-30 (sense) and 50-TCCACCACC
CTGTTGCTGTA-30 (antisense) generating a 480-bp fragment. The
sets of above primers were based on rat cDNA sequences (GenBank,
AF030358 for fractalkine, U57441 for MCP-1, U06436 for RANTES,
and NM017008 for GAPDH) and selected by software-aided analysis
(Primer Premier 5.0) and synthesized by Takara Co. (Osaka, Japan).
PCR-amplified cDNA was separated by 3% agarose gel electrophor-
esis and visualized with ethidium bromide. Semiquantitative
analysis was performed using UVP-gel densitometry (UVP Co.,
San Gabriel, CA, USA). Arbitrary unit¼ (Afractalkine, MCP-1, or RANTES/
AGAPDH) 100%.
ELISA of chemokines
Growth-arrested mesangial cells (2 106/well) were pretreated with
or without LXA4 at different concentrations, PD98059 (40 mmol/l)
or LY294002 (25 mmol/l) for 30 min, or PDTC (50 mmol/l) for 1 h,
and the coincubation was continued for 6–48 h after addition of
CTGF in RPMI-1640 containing 0.5% FCS. The supernatants were
collected for measurement of soluble fractalkine, MCP-1, and
RANTES using the ELISA kit following the manufacturer’s
instructions.
In vitro chemotaxis assay
Conditioned media obtained from CTGF-activated cells were placed
in the lower compartment of Transwell cluster plates (Costa
Corning, Cambridge, MA, USA) with two-compartment chambers
separated by a polycarbonate membrane filter. THP-1 cells (5 104
cells) were added to the upper chamber and incubated at 371C for
254 Kidney International (2006) 69, 248–256
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4 h. After incubation, the membrane filter was stained with
hematoxylin and eosin and the monocytes that migrated from the
upper chamber were counted in duplicate per  100 high-power
field with a light microscope. A goat anti-rat fractalkine, MCP-1,
RANTES or goat IgG was used in the chemotaxis assay media to
determine the biological specificity of the above chemokines
produced by the cells to stimulate monocyte transmigration.
Western blot analysis
Western blot analysis was performed as described previously.12 The
blots were incubated with primary rabbit anti-rat antibodies against
P-p42/44 MAPK, P-PI3-K, or P-Akt at 1:2000 dilution for 1 h
followed by incubating with horseradish peroxidase-conjugated goat
anti-rabbit IgG antibodies at 1:2000 final dilution. For all
experiments, equal loading was confirmed by reprobing with the
antibodies against total p42/44 MAPK, total PI3-K, or total Akt
(1:1000 each). Semiquantitative analysis was performed using UVP-
gel densitometry. Arbitrary unit¼ (AP-p42/44 MAPK/Ap42/44 MAPK or
AP-PI3-K/API3-K or AP-Akt/AAkt) 100%.
Electrophoretic mobility shift assay of NF-jB activity
Growth-arrested mesangial, cells were preincubated with or without
LXA4, PD98059, LY294002, or PDTC as mentioned above, and the
coincubation was continued for 1 h after addition of CTGF in
RPMI-1640 containing 0.5% FCS. Electrophoretic mobility shift
assay was performed as described previously.12
Transfection with pcDNA3.1/LRHG
The LRHG was amplified by PCR from cDNA of mouse testis as
template. The primer pair of murine LRHG was selected based on
mRNA sequence of LRHG from GenBank (NCBI ID: AY138248).
The sense primer (50-CCCAAGCTTGGGCCACCATGGAATCCAA
CTACTCCATCC-30) had an incorporated HindIII site and Kazak
sequence GCCACC to promote translation. The antisense primer (50-
CCGCTCGAGCGGTGGGGCCTTTAACTCAAT-30) had an incorpo-
rated XhoI site. After RT-PCR amplification, the LRHG was inserted
in the plasmid pGEM-T and then transformed into Escherichia coli
JM109. Positive clones were amplified, digested with HindIII and
XhoI restriction endonucleases, screened and identified by sequen-
cing. The eucaryotic expression vector pcDNA3.1/LRHG containing
6 histidine gene was constructed. Sequence analysis showed that
the gene homology between cloned LRHG and reported LRHG by
GenBank was 100%. The recombinant plasmid pcDNA3.1/LRHG-his
or empty pcDNA3.1 vector was transfected into the cells using
Lipofectamine 2000 transfection reagent following the manufac-
turer’s protocol. Positive clones were collected and amplified
following incubation with G418 for 3 weeks. The stable expression
of LXA4 homologue receptor in mesangial cells was demonstrated by
Western blot using the antibodies against 6 histidine.
Statistical analysis
Results are expressed as mean7standard error of the mean (s.e.m.).
Experimental data were analyzed using one-way analysis of variance
followed by S-N-K test (Q test) by Statistical Package for Social
Sciences version 10.0 (SPSS, Chicago, IL, USA). Differences were
considered to be statistically significant when Po0.05.
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